Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Effects on Insulin Sensitivity in T2D
NCT00831779Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2009
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Apr 2009; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00831779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00831779.